Hyprosha 250 Injection contains Hydroxyprogesterone 250 mg, a synthetic progestogen used primarily in the prevention of preterm birth and management of various gynecological conditions. Hydroxyprogesterone acts by mimicking the natural hormone progesterone, which plays a crucial role in maintaining pregnancy and regulating the menstrual cycle. This injectable formulation is indicated for use in women at risk of preterm labor, particularly those with a history of spontaneous preterm birth, to reduce the incidence of early delivery and associated neonatal complications. Additionally, Hyprosha 250 may be employed in the treatment of amenorrhea, abnormal uterine bleeding, and as part of hormone replacement therapy in certain clinical scenarios. The administration of Hyprosha 250 Injection is typically intramuscular, with dosage and duration tailored to the patient’s specific condition and response to therapy. Common side effects may include injection site reactions, headache, nausea, and fatigue, while serious adverse effects are rare but warrant medical attention. Contraindications include known hypersensitivity to hydroxyprogesterone or progestogens, active thrombophlebitis, and certain hormone-sensitive malignancies. Hyprosha 250 Injection should be used under strict medical supervision, with careful consideration of patient history and ongoing monitoring to ensure safety and therapeutic efficacy.